NeuroTherapia, Inc.

NeuroTherapia, Inc., founded in 2015 as a Cleveland Clinic spin-out, is a clinical-stage biotechnology company focused on developing oral small-molecule therapeutics for neuroinflammatory disorders, including Alzheimer's, Parkinson's, ALS, multiple sclerosis, and neuropathic pain. The company has completed Phase 1a/b trials showing safety, favorable pharmacokinetics, and early cognitive benefits. In 2025, NeuroTherapia secured EMA approval to begin a Phase IIa trial in Alzheimer's patients across Europe. Product & Service Line Breakdown: NTRX-07: Lead Therapeutic Candidate - Mechanism: Orally available, selective CB2 receptor agonist targeting microglia to reduce neuroinflammation while preserving beta-amyloid clearance. - Preclinical Efficacy: Demonstrated cognitive restoration and neuronal protection in Alzheimer's and neuropathic pain animal models. - Clinical Development: - Phase 1a/b: Confirmed safety, favorable pharmacokinetics, preliminary signs of cognitive improvement and biomarker response in healthy volunteers and early-stage AD patients. - Phase IIa: Approved by EMA in February 2025; assessing safety, biomarker engagement, and cognitive outcomes in a 28-day, randomized, double-masked trial across multiple European sites.